膀胱癌全基因组关联研究揭示新的生物学与转化启示
该研究对32项研究(13,790例膀胱癌病例和343,502例欧洲血统对照)的全基因组基因型数据进行荟萃分析,识别出多个新的膀胱癌易感位点,使全基因组显著性的独立标记数达到24个,并构建多基因风险评分以分层终身风险。
要点
- 识别出6p22.3、7q36.3、8q21.13、9p21.3、10q22.1、19q13.33等新易感位点,并改善三个已知区域的信号。
- 基于24个独立标记的多基因风险评分每增加一个标准差,膀胱癌风险比值比为1.49(95%CI 1.44-1.53)。
- 多基因风险评分显示吸烟者与非吸烟者的终身风险在第1与第10十分位之间约相差四倍。
核心结论
- 报告了与膀胱癌风险相关的新位点,为其生物学基础提供线索。
- 利用24个独立标记构建的多基因风险评分可分层终身风险,结合吸烟史和其他既定风险因素,有潜力为未来膀胱癌筛查提供信息。
研究设计与样本
- 对32项研究(13,790例膀胱癌病例和343,502例欧洲血统对照)的新发和现有全基因组基因型数据进行荟萃分析。
- 采用逻辑回归模型评估遗传变异的对数加性关联,并使用固定效应模型进行荟萃分析。
- 进行分层分析以评估性别和吸烟状态的效应修饰,并基于已知和新易感变异生成多基因风险评分,检验其与吸烟的交互作用。
主要发现
- 识别出多个新的膀胱癌易感位点(6p22.3、7q36.3、8q21.13、9p21.3、10q22.1、19q13.33)以及三个已知区域(4p16.3、5p15.33、11p15.5)的改善信号,使全基因组显著性(p < 5 × 10-8)的独立标记数达到24个。
- 4p16.3(FGFR3/TACC3)位点与女性风险强于男性相关(交互作用p = 0.002)。
- 吸烟状态与8p22(NAT2;乘性交互作用p值[pM-I] = 0.004)、8q21.13(PAG1;pM-I = 0.01)和9p21.3(LOC107987026/MTAP/CDKN2A;pM-I = 0.02)遗传变异之间的交互作用增加膀胱癌风险。
- 基于24个独立全基因组关联研究标记的多基因风险评分(每标准差增加的比值比1.49,95%置信区间1.44-1.53),在两个前瞻性队列(UK Biobank、PLCO试验)中显示可比结果,并显示吸烟者和非吸烟者中根据多基因风险评分(如第1与第10十分位)的终身膀胱癌风险约相差四倍。
局限性
- 原文在结果与局限性部分报告了多个新位点及信号改善,但未明确陈述具体局限性内容;原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genomic regions identified by genome-wide association studies (GWAS) for bladder cancer risk provide new insights into etiology. OBJECTIVE: To identify new susceptibility variants for bladder cancer in a meta-analysis of new and existing genome-wide genotype data. DESIGN, SETTING, AND PARTICIPANTS: Data from 32 studies that includes 13,790 bladder cancer cases and 343,502 controls of European ancestry were used for meta-analysis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Log-additive associations of genetic variants were assessed using logistic regression models. A fixed-effects model was used for meta-analysis of the results. Stratified analyses were conducted to evaluate effect modification by sex and smoking status. A polygenic risk score (PRS) was generated on the basis of known and novel susceptibility variants and tested for interaction with smoking. RESULTS AND LIMITATIONS: Multiple novel bladder cancer susceptibility loci (6p.22.3, 7q36.3, 8q21.13, 9p21.3, 10q22.1, 19q13.33) as well as improved signals in three known regions (4p16.3, 5p15.33, 11p15.5) were identified, bringing the number of independent markers at genome-wide significance (p < 5 × 10-8) to 24. The 4p16.3 (FGFR3/TACC3) locus was associated with a stronger risk for women than for men (p-interaction = 0.002). Bladder cancer risk was increased by interactions between smoking status and genetic variants at 8p22 (NAT2; multiplicative p value for interaction [pM-I] = 0.004), 8q21.13 (PAG1; pM-I = 0.01), and 9p21.3 (LOC107987026/MTAP/CDKN2A; pM-I = 0.02). The PRS based on the 24 independent GWAS markers (odds ratio per standard deviation increase 1.49, 95% confidence interval 1.44-1.53), which also showed comparable results in two prospective cohorts (UK Biobank, PLCO trial), revealed an approximately fourfold difference in the lifetime risk of bladder cancer according to the PRS (e.g., 1st vs 10th decile) for both smokers and nonsmokers. CONCLUSIONS: We report novel loci associated with risk of bladder cancer that provide clues to its biological underpinnings. Using 24 independent markers, we constructed a PRS to stratify lifetime risk. The PRS combined with smoking history, and other established risk factors, has the potential to inform future screening efforts for bladder cancer. PATIENT SUMMARY: We identified new genetic markers that provide biological insights into the genetic causes of bladder cancer. These genetic risk factors combined with lifestyle risk factors, such as smoking, may inform future preventive and screening strategies for bladder cancer.
引用
- Koutros S, Kiemeney LA, Pal Choudhury P, et al. Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights. Eur Urol. 2023. PMID: 37210288. doi:10.1016/j.eururo.2023.04.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。